CSC: AI Reshaping Traditional Pharma R&D Paradigm

The notable signal here is framing, not novelty: a sell-side brokerage is now treating AI as infrastructure across the entire discovery pipeline rather than a single-point tool, which matters for how pharma R&D budgets and outsourcing get allocated. The Eroom's Law reference gives the argument a macro hook — declining R&D productivity as the problem AI is being sold against — though the note offers no evidence on whether success rates actually improve in practice. Worth watching is whether this thesis stays at the level of brokerage commentary or starts showing up in disclosed pipeline economics and partnership structures.